BPMC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 41 cases where BPMC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 53 cases where BPMC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
BPMC moved above its 50-day moving average on November 18, 2024 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BPMC advanced for three days, in of 303 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for BPMC moved out of overbought territory on November 12, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on December 11, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on BPMC as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for BPMC turned negative on December 04, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BPMC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BPMC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BPMC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.342) is normal, around the industry mean (14.664). P/E Ratio (0.000) is within average values for comparable stocks, (87.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.783). BPMC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (13.661) is also within normal values, averaging (260.687).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
a developer of cancer therapies that harness the growing understanding of the molecular blueprint of cancer
Industry Biotechnology
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
VAMO | 30.73 | N/A | N/A |
Cambria Value and Momentum ETF | |||
HLAL | 54.98 | N/A | N/A |
Wahed FTSE USA Shariah ETF | |||
BUXX | 20.32 | -0.01 | -0.05% |
Strive Enhanced Income Short MaturityETF | |||
EVUS | 29.31 | -0.17 | -0.57% |
iShares ESG Aware MSCI USA Value ETF | |||
DFSV | 31.74 | -0.45 | -1.41% |
Dimensional US Small Cap Value ETF |
A.I.dvisor indicates that over the last year, BPMC has been loosely correlated with BEAM. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BPMC jumps, then BEAM could also see price increases.
Ticker / NAME | Correlation To BPMC | 1D Price Change % | ||
---|---|---|---|---|
BPMC | 100% | +1.14% | ||
BEAM - BPMC | 46% Loosely correlated | -1.21% | ||
KRYS - BPMC | 44% Loosely correlated | +0.85% | ||
DNLI - BPMC | 44% Loosely correlated | -0.30% | ||
BBIO - BPMC | 43% Loosely correlated | +0.40% | ||
PDSB - BPMC | 43% Loosely correlated | +1.29% | ||
More |